SCHEDULE: FMR LLC Discloses 15% Stake in Enliven Therapeutics
Beneficial Ownership Filing (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 15.0% of Enliven Therapeutics Inc.'s common stock as of June 30, 2026.
Summary
- FMR LLC and Abigail P. Johnson, through various entities, collectively beneficially own 10,713,540.41 shares of Enliven Therapeutics Inc. common stock.
- This holding represents 15.0% of the class of securities.
- The filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership or a periodic update.
- The reporting persons are identified as investment advisors (IA) and banks (BK) through their respective entities.
- Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant institutional holding without new strategic information.
Positives
- Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in the company.
- The filing confirms a substantial holding of 15.0% of the outstanding common stock.
Negatives
- No new strategic information or operational updates are provided in this filing.
- The filing is a routine disclosure and does not offer insights into future performance.
Risks
- The filing does not explicitly mention any new risks or challenges.
- Potential for future changes in FMR LLC's stake could impact share price.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.
Management Comments
- FMR LLC and Abigail P. Johnson, through their respective entities, are reporting their beneficial ownership of Enliven Therapeutics Inc. common stock.
- Abigail P. Johnson's role as Director, Chairman, and CEO of FMR LLC is noted, along with the Johnson family's predominant ownership and voting control of FMR LLC.
Industry Context
StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson is a standard disclosure for significant institutional investors. It indicates a substantial, established position in Enliven Therapeutics, but does not signal new strategic initiatives or changes in the company's operational direction.
Stakeholder Impact
- Shareholders: The significant stake held by FMR LLC and Abigail P. Johnson may provide a degree of stability to the stock, but also indicates a large holder whose future actions could influence the market.
- Management: The filing does not directly impact management, but confirms a major institutional investor's continued interest.
- Creditors: No direct impact is indicated.
Next Steps
- Continue to monitor future filings from FMR LLC and Abigail P. Johnson for any changes in their beneficial ownership.
- Observe Enliven Therapeutics Inc.'s operational and financial performance independently of this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-10 | Filing date of previous Schedule 13G by FMR LLC. |
| 2023-01-31 | Filing date of previous Schedule 13G by FMR LLC. |
| 2026-06-30 | Date of event requiring filing of this statement (ownership as of this date). |
| 2026-08-05 | Date of joint filing agreement and signature date. |
Keywords
Enliven Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Advisor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.